Bacteriophage Cocktail for the Prevention of Biofilm Formation by Pseudomonas aeruginosa on Catheters in an In Vitro Model System

Abstract

Microorganisms develop biofilms on indwelling medical devices and are associated with device-related infections, resulting in substantial morbidity and mortality. This study investigated the effect of pretreating hydrogel-coated catheters with Pseudomonas aeruginosa bacteriophages on biofilm formation by P. aeruginosa in an in vitro model. Hydrogel-coated catheters were exposed to a 10 log 10 PFU ml ؊1 lysate of P. aeruginosa phage M4 for 2 h at 37°C prior to bacterial inoculation. The mean viable biofilm count on untreated catheters was 6.87 log 10 CFU cm ؊2 after 24 h. The pretreatment of catheters with phage reduced this value to 4.03 log 10 CFU cm ؊2 (P < 0.001). Phage treatment immediately following bacterial inoculation also reduced biofilm viable counts (4.37 log 10 CFU cm ؊2 reduction; P < 0.001). The regrowth of biofilms on phage-treated catheters occurred between 24 and 48 h, but supplemental treatment with phage at 24 h significantly reduced biofilm regrowth (P < 0.001). Biofilm isolates resistant to phage M4 were recovered from catheters pretreated with phage. The phage susceptibility profiles of these isolates were used to guide the development of a five-phage cocktail from a larger library of P. aeruginosa phages. The pretreatment of catheters with this cocktail reduced the 48-h mean biofilm cell density by 99.9% (from 7.13 to 4.13 log 10 CFU cm ؊2 ; P < 0.001), but fewer biofilm isolates were resistant to these phages. These results suggest the potential of applying phages, especially phage cocktails, to the surfaces of indwelling medical devices for mitigating biofilm formation by clinically relevant bacteria.Indwelling medical devices of various kinds may become colonized with microorganisms, resulting in the formation of microbial biofilms (16). Biofilm-associated organisms are tolerant to antimicrobial agents, can evade the host immune system, and can act as a nidus for infection (16). As a result, device-related infections, such as catheter-associated bloodstream infections, cause substantial morbidity and mortality among specific patient populations (9). Attributable mortality rates for healthcare-associated bloodstream infections have been estimated to be 25% (44).A number of novel strategies have been proposed to more effectively prevent and control device-associated biofilms, either by minimizing microbial attachment to device surfaces or by targeting the biofilm after it has developed. One such strategy is to use bacteriophages (phages) (17). Phages have been used for the treatment of infectious diseases in plants (26), animals (6), and humans (33,39,43). The use of phages to control biofilms has potential for several reasons. Phages can replicate at the site of an infection, thereby increasing in numbers where they are most required. During the lytic replication cycle, the infection of a bacterial host cell by a single phage virion will result in the production of dozens or hundreds of progeny phage, depending on the particular phage and host strains. Some phages also have been shown to...

Vers une pharmacopée anti-infectieuse innovante : points forts de l’actualité

“…À l'inverse, la tige de HA est conservée chez toutes les souches, et des anticorps reconnaissant la tige de HA neutralisent le virus avant son entrée dans les cellules cibles [2]. Koday et al ont appliqué une approche d'optimisation de ligand assistée par ordinateur pour synthétiser une protéine liant la tige de HA de multiples sous-types avec une forte affinité [3]. Les auteurs ont généré une large banque de mutants à partir d'un ligand de HA déjà connu, ont sélectionné le mutant présentant la meilleure affinité contre sept sous-types de HA et l'ont identifié par séquençage à haut neutralisé, il peut infecter plus facilement les macrophages, ses cellules cibles, qui expriment des récepteurs pour la région Fc des anticorps [2].…”

“…Comme il existe quatre sérotypes différents de DENV, une sérothéra-pie impose donc l'utilisation d'anticorps de large spectre capables de neutraliser efficacement tous les sous-types. Dans cette optique, Robinson et al [3] ont optimisé les propriétés thérapeutiques d'un anticorps anti-DENV déjà décrit, en modélisant in silico la surface d'interaction entre l'anticorps et l'épitope issu des protéines virales d'enveloppe des quatre sérotypes, et en la modifiant par mutagenèse dirigée. Après validation in vitro, les auteurs ont montré que l'anticorps réduisait la charge virale chez la souris infectée et bloquait l'apparition de fièvre hémorragique, tout en prévenant la facilitation.…”

“…Leur utilisation permettrait d'éradiquer uniquement l'espèce bactérienne ciblée, contrairement aux antibiotiques à large spectre, actifs aussi contre des espèces bénéfiques de la flore commensale. Plusieurs travaux ont confirmé l'efficacité de phages spécifiques de S. aureus, utilisés individuellement ou en association [2,3]. Cependant, l'hypothèse d'une efficacité limitée par le pouvoir neutralisant des anticorps humains antiphages induits lors du traitement a été émise [4] Marie Naoumenko, Kamela Nikolla, Laurine Noblecourt, Christophe Gilbert Le développement d'une résistance immunitaire contre les phages peut-il limiter l'efficacité de la phagothérapie ?…”

Bacteriophage K for reduction ofStaphylococcus aureusbiofilm on central venous catheter material

“…Prior investigations suggest that the application of bacteriophage to indwelling medical devices, such as intravascular catheters, could provide a strategy for the reduction in biofilm formation by clinically relevant bacteria such as Staphylococcus. 19,20 The purpose of this study was to evaluate bacteriophage antimicrobial therapy application for eliminating Staphylococcus aureus biofilm on central venous catheter material.…”

“…[16][17][18] Phage therapy has also been proposed to be used against multidrug-resistant bacteria, and may reduce the use of antimicrobial drugs and the spread of antimicrobial resistance. 9,15,[17][18][19][20][21] Despite the potential advantages of phage therapy, only a few studies have concentrated on its direct application toward biofilm control and treatment. Prior investigations suggest that the application of bacteriophage to indwelling medical devices, such as intravascular catheters, could provide a strategy for the reduction in biofilm formation by clinically relevant bacteria such as Staphylococcus.…”